Top 50 Biofoundry

This company develops an AI-powered platform for bioproduction, integrating a genome-to-factory model with a precision biofoundry. They utilize automated wet-lab processes and proprietary data collection to accelerate strain development for industrial ingredients. The platform supports standardized bioprocesses to ensure efficient scaling and high-quality product output.

<name>Intrinsic Foundries</name> <description>Intrinsic Foundries operates a Carbon Biofoundry platform that captures industrial CO₂ and converts it into high-value biochemicals and materials. The company combines photobioreactor technology, adaptive cultivation systems, and modular engineering to deliver scalable, efficient biomanufacturing. Their approach creates a circular economy by

The startup has developed a genetic engineering platform that enables long-chain DNA synthesis for the production of microbes and combinatorial DNA libraries. This technology addresses the limitations of traditional DNA synthesis methods, facilitating more efficient and scalable genetic engineering applications for medical professionals.

The startup operates a biotechnology platform that utilizes synthetic biology and bio-foundry services to address environmental degradation through sustainable practices. By providing tailored solutions for environmental challenges, the company enables clients to enhance their ecological impact and contribute to a sustainable future.

Foundry BioSciences develops protein language models to engineer optimized proteins aimed at addressing aging concerns and extending longevity. Their AI-driven platform accelerates the discovery and design of novel protein sequences with significantly enhanced activity compared to natural variants. This technology reduces protein engineering timelines from years to months, offering scalable solutions for therapeutic applications in healthspan improvement.

Evonetix is developing a desktop platform that synthesizes gene-length DNA with high accuracy and scalability using a novel approach to DNA synthesis. This technology provides researchers with rapid access to precise genetic material, addressing the limitations of current gene synthesis methods that hinder innovation in healthcare and biotechnology.

The startup develops a synthetic biology plant architecture that utilizes proprietary hyper-integration algorithms and precision fermentation to create customized modular plant systems at scale. This approach significantly reduces the time and costs associated with bringing synthetic biology products to market, addressing inefficiencies in traditional biomanufacturing processes.

The company offers an AI‑driven synthetic biology platform that designs and engineers microbial strains to produce bio‑based chemicals and polymers. Its automated design‑build‑test‑learn workflow, real‑time fermentation analytics, and scale‑up simulation tools enable customers to develop high‑yield strains in months and integrate them into existing bioprocessing facilities, reducing carbon emissions and capital costs.

The startup develops modular bioreactors that provide cost-effective solutions for biomanufacturing processes. These bioreactors enable scalable production of biological products, addressing the high capital costs and inflexibility associated with traditional bioreactor systems.

The startup offers an automated protein manufacturing system that enables users to produce biologics efficiently and cost-effectively. This technology addresses the lengthy development cycles and high costs associated with creating new medicines and bio-based products.

The company offers a modular microbial engineering platform that designs, builds, and optimizes production strains to convert renewable feedstocks into commodity and specialty chemicals. It integrates CRISPR‑based genome editing, AI‑driven metabolic pathway prediction, high‑throughput strain screening, and cloud‑based process analytics to deliver scalable, low‑energy biocatalytic routes that meet industrial throughput and regulatory standards.

Huili Bio is a synthetic biology platform that utilizes computational design to engineer enzymes for specific biochemical applications. The platform aims to enhance the efficiency of bioprocesses in industries such as pharmaceuticals and agriculture by providing tailored enzyme solutions.

Becoming offers an end‑to‑end synthetic biology platform that designs, builds, and optimizes microbial cell factories for industrial bioproduction. The system combines genome‑scale pathway modeling, high‑throughput CRISPR editing, AI‑driven strain optimization, and automated fermentation control, with cloud‑based workflow management for scalable, GMP‑ready manufacturing. It serves chemical, material, and biotech companies seeking bio‑based alternatives to petrochemical processes.

Arsenale provides a fully integrated biomanufacturing platform that combines hardware, data, and AI to enable fast, low-cost production at an industrial scale. This end-to-end system manages the entire production value chain, from organism design in the lab to large-scale industrial output. The platform utilizes proprietary micro-scale reactors and large-capacity BioYards to ensure precision, scalability, and continuous learning for economically viable biomanufacturing.

Constructive.Bio utilizes a dual-technology platform that combines de novo genome synthesis and engineered translation to create programmable biomolecules with high fidelity. This approach addresses the limitations of traditional biomanufacturing by enabling the production of customized bioproducts, including phage-resistant strains and next-generation therapeutics.

Anthology generates diverse, designer genomes by combining genetic parts across species boundaries to create novel biological capabilities. This technology enables the scalable and efficient production of functional proteins for human nutrition, improved animal health solutions, and carbon-neutral bioproduction from waste feedstocks. The resulting designer genomes maximize the practical impact of biology in addressing major global challenges.

Rare Molecule Foundry uses advanced AI models to design novel molecules, proteins, enzymes, and peptides in silico. This computational platform accelerates the discovery and optimization of compounds for biopharma and research applications. The company reduces time and uncertainty in the molecular innovation pipeline by providing precision-driven design before wet lab synthesis.

Herlab utilizes synthetic biology and artificial intelligence to develop specialized microbial expression systems for the production of complex recombinant proteins. The platform addresses the challenge of producing human-like glycosylated proteins and other difficult-to-manufacture proteins for applications in biopharma, biocosmetics, and nutrition within a rapid timeframe of under 10 weeks.

This company uses AI-driven protein design to optimize the production of biological molecules and microbes. Their technology enables enterprises to design more stable and efficient enzymes for applications in synthetic biology, food, cosmetics, and environmental protection.

Simmbion engineers bacteria, fungi, and viruses to create experimental solutions for the production of biologics. The company addresses challenges in biologics manufacturing by enhancing yield and efficiency through synthetic biology techniques.

Pow.bio has developed a high-efficiency fermentation platform that decouples biomass growth from product production, addressing issues of contamination and genetic drift in biomanufacturing. This technology enables manufacturers to achieve 2-5 times more product output while reducing production costs by 40-70%.

Biocatsyn specializes in synthetic biology and green biomanufacturing to produce sustainable biological products. The company addresses the need for environmentally friendly manufacturing processes in various industries by utilizing advanced biotechnological methods.

Pearl Bio utilizes genome and ribosome engineering to create novel biomaterials with customizable properties for smart biologics. This technology addresses the limitations of traditional biologics by enabling the production of materials with diverse chemistries that were previously unattainable.

Melonfrost is a biotechnology company focused on developing advanced bioprocessing techniques to enhance the efficiency of microbial production systems. The company addresses the challenge of high production costs in biotechnology by optimizing yield and reducing resource consumption in the manufacturing of bio-based products.

64x Bio develops a high throughput genome engineering platform that accelerates the discovery of optimized mammalian cell lines for cell and gene therapies. This technology enables pharmaceutical and biotechnology companies to efficiently design and manufacture next-generation therapeutics, addressing the challenges of traditional cell line development.

Synonym develops biomanufacturing infrastructure and a dynamic database of contract manufacturers to facilitate the commercialization of next-generation bioproducts. By providing techno-economic analysis and lifecycle assessments, the company helps businesses scale production efficiently while addressing the challenges of supply chain sustainability and decarbonization.

Asimov develops a platform that integrates synthetic biology, biophysical simulations, and machine learning to engineer mammalian cell lines for the production of biologics and gene therapies. This technology enables healthcare companies to optimize the design and manufacturing processes of genetic circuits, improving efficiency and scalability in therapeutic applications.

Symic Bio provides a synthetic biology platform that designs and assembles custom biological circuits to generate drug candidates across small‑molecule and biologic modalities. The system combines machine‑learning‑driven computational design, CRISPR‑compatible modular chassis, and automated high‑throughput screening, feeding results into a cloud‑native analytics suite for rapid lead identification and safety profiling. It targets pharmaceutical and biotech R&D teams seeking faster, more efficient discovery of high‑specificity therapeutics.

Yuanyi Biotech specializes in synthetic biology, utilizing engineered metabolic pathways and high-throughput screening to develop microbial strains for efficient production of carotenoids, enzymes, and peptides. The company addresses the need for cost-effective and scalable bioproduction solutions in industries such as aquaculture and cosmetics.

Jushu Biotech develops a high-throughput biosensing platform utilizing CRISPR-based genome editing and ultrahigh-throughput droplet microfluidics to optimize microbial and mammalian cell lines for various applications in health, biochemicals, and agriculture. The company addresses the inefficiencies in traditional cell engineering by enabling rapid iteration and selection of engineered cells, significantly enhancing production capabilities.

The startup develops a biotechnology platform that utilizes living organisms and molecular biology techniques to create healthcare-related products. This approach enables clients to access effective treatments, enhancing the overall quality of human life.

Cellular Intelligence offers a platform that combines synthetic biology with computational design to create programmable cellular systems. Their workflow lets biotech and pharma companies model, synthesize, and test custom genetic circuits and pathways, reducing development time and variability for therapeutics, diagnostics, and industrial bioproducts.

Mirai Bio offers end-to-end development capabilities for biopharmaceuticals, utilizing advanced bioprocessing techniques to streamline product development. The company addresses inefficiencies in the drug development pipeline, enabling faster time-to-market and reduced costs for biotech firms.

The company offers autonomous laboratory platforms that replace manual bench work with modular robotic workcells capable of high‑precision liquid handling, incubation, and integrated plate reading. Users submit experiment protocols via a natural‑language interface or REST API, and the cloud‑based system executes, monitors, and stores raw assay data with analytics dashboards, while a remote “cloud lab” option enables experiments to be run on a shared facility. The solution targets biotech, pharmaceutical, synthetic biology, academic laboratories, and contract research organizations seeking high‑throughput, reproducible experimentation.

This biotechnology company designs novel protein backbones and enzymes for various industrial applications. They specialize in directed evolution and enzyme screening to optimize protein function, offering advanced solutions for clients in the biotechnology sector.

Adaptyv Bio offers an automated cloud lab platform that conducts protein assays and delivers clean, labeled data for AI-driven protein design within three weeks. The service integrates ordering, experiment management, and data analysis through a comprehensive API, enabling seamless incorporation into existing workflows. Transparent per‑protein pricing and real‑time progress updates help teams accelerate lab‑in‑the‑loop protein engineering cycles.

Enzymit develops a cell-free bioproduction platform utilizing computational protein design and high-throughput testing to create novel enzymes for various industries, including biochemicals and health. This technology addresses the inefficiencies and high costs associated with traditional enzymatic manufacturing processes, enabling faster and more sustainable production.

Zhonghe Gene develops enzyme-driven DNA biosynthesis technology, offering automated solutions for short and long-chain DNA synthesis and gene assembly. Their products enable efficient, cost-effective gene synthesis for applications in synthetic biology, biomedicine, and DNA data storage, addressing the need for accessible and scalable genetic engineering tools.

This biopharmaceutical company develops a platform that optimizes cell line development (CLD) for biomanufacturing, aiming to increase drug yields and reduce production costs. Their proprietary technology identifies the most efficient cell lines for specific biomanufacturing processes, offering end-to-end CLD services.

Camena Bioscience develops the gSynth® platform, a TdT-free enzymatic DNA synthesis technology that enables the high-throughput production of synthetic genes of any sequence, length, and complexity. This technology addresses the limitations of traditional DNA synthesis methods, which struggle to produce long, accurate synthetic DNA at scale, thereby facilitating advancements in personalized mRNA vaccines, cell and gene therapies, and CRISPR applications.

Future Fields utilizes its EntoEngine™ platform to produce custom recombinant proteins using fruit flies, enabling the scalable manufacturing of difficult-to-express proteins. This approach addresses the challenges of high production costs and environmental impact associated with traditional protein synthesis methods.

The startup develops machine-learning tools to design cell factories capable of producing a wide range of products, including food, fabrics, and medicines. By simplifying the complex process of cellular manufacturing, the company aims to replace traditional farms and factories, promoting a more sustainable production model.

This startup manufactures and provides bio-based products for synthetic biology, focusing on negative carbon new materials, polymer monomers, and high-value compounds. They enable clients to access sustainable alternatives for various industrial applications.

Proton Bio provides contract development and manufacturing organization (CDMO) services specializing in gene and cell therapy. The company focuses on producing high-quality therapeutic products to meet the growing demand for advanced treatments in genetic disorders and cancer.

Anaula provides autonomous bioreactor platforms that automate cell culture and fermentation for biotech and pharmaceutical research. The systems combine sensor-driven monitoring, AI-based control, and remote management to improve reproducibility and reduce labor. Revenue is generated through hardware sales, software licensing, and consumable kits.

Curve develops modular production systems, like BIOBRIC, that combine hardware and data simulations to optimize precision fermentation and cell cultivation. This technology bridges the cost gap between basic fermenters and high-cost bioreactors, enabling commercially viable scale-up for biomanufacturing. The company focuses on reducing OPEX and CAPEX to make sustainable protein and ingredient production accessible across various industries.

Junji Gene provides intelligent laboratories for gene synthesis, utilizing advanced automation and precision techniques to enhance the efficiency of genetic material production. The company also facilitates the sourcing of raw materials for in vitro diagnostic kits, addressing the challenges of supply chain reliability in the diagnostics sector.

Aether Bio develops machine learning algorithms and proprietary robotic hardware to engineer enzymes for the production of complex biochemical compounds. This technology enables manufacturers to create novel products at significantly reduced costs by efficiently indexing and searching trillions of enzyme sequences.

Fermelanta develops innovative microbial production processes for plant-based chemicals using synthetic biology. The company engineers cell factories to sustainably and scalably produce valuable molecules derived from nature. These plant secondary metabolites serve as raw materials for pharmaceuticals, cosmetics, and health foods.

The startup operates a synthetic biology platform that designs and manufactures biomedicines by creating product-specific libraries of synthetic genetic parts. By utilizing bioinformatic analysis of genome-scale data, the company enables clients to engineer novel biomolecules tailored to specific therapeutic properties.